Organophosphate poisoning by self-injection is rare. Current case report describes a man with subcutaneous self-injected OP. poisoning presenting with delayed. He was treated with pralidoxime. Through the observation, dose and the time between poisoning until time to start treatment we can conclude different presentations and outcomes of OP poisoning.

Organophosphate (OP) poisoning is prevalent in developing countries. Toxicity occurs by voluntary injection, inhalation, and absorption. Self-injection is rare. The current case report describes a 61-y/o male with subcutaneous self-injected one cc OP poisoning presenting with delayed drowsiness, nausea, and vomiting. He was treated and presented a good clinical response to treatment with pralidoxime and had a successful recovery. Diagnosis of OP compound toxicity by the parenteral route is a challenge. By observing patients, the dose, and the time between poisoning until the time to start treatment, we can conclude different presentations and outcomes of OP poisoning.